Iama Therapeutics
IAMA Therapeutics is a clinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and started the Phase 1 clinical trial in January 2024. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
9
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Iama Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- MB
Marco Borgogno
Head Chemistry & Cmc · Manufacturing & Production
EmailPhone - AS
Annalisa Savardi
Head Preclinical Development · Research & Development
EmailPhone - TM
Torsten M. Madsen
Hoba Therapeutics · Other
EmailPhone
Showing 3 of 4 verified contacts
Top roles at Iama Therapeutics
4 distinct titles indexed · top 4 shown.
- 1head chemistry & cmc
- 1head preclinical development
- 1hoba therapeutics
- 1scientist
Sign up to unlock all 4 contacts at Iama Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Iama Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.